Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

Transcriptase Inhibitor ◽

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

AIDS ◽

10.1097/qad.0b013e32834d0c20 ◽

2011 ◽

Vol 25 (18) ◽

pp. 2269-2278 ◽

Cited By ~ 19

Author(s):

Richard H. Haubrich ◽

Sharon A. Riddler ◽

Heather Ribaudo ◽

Gregory DiRenzo ◽

Karin L. Klingman ◽

...

Keyword(s):

Hiv Infection ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Initial highly-active antiretroviral therapy with a protease inhibitor versus a nonnucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect metaanalyses

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70040-3 ◽

2007 ◽

Vol 2007 ◽

pp. 61-62

Author(s):

D.R. Snydman

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Highly Active Antiretroviral Therapy ◽

Transcriptase Inhibitor ◽

Highly Active ◽

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing nonnucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: openlabel randomised trial

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70039-7 ◽

2007 ◽

Vol 2007 ◽

pp. 60-61

Author(s):

D.R. Snydman

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Randomised Trial ◽

Transcriptase Inhibitor ◽

Immune Reconstitution Is Comparable in Antiretroviral‐Naive Subjects after 1 Year of Successful Therapy with a Nucleoside Reverse‐Transcriptase Inhibitor– or Protease Inhibitor–Containing Antiretroviral Regimen

The Journal of Infectious Diseases ◽

10.1086/379041 ◽

2003 ◽

Vol 188 (10) ◽

pp. 1444-1454 ◽

Cited By ~ 24

Author(s):

Alan L. Landay ◽

John Spritzler ◽

Harold Kessler ◽

Donna Mildvan ◽

Minya Pu ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Immune Reconstitution ◽

Transcriptase Inhibitor ◽

Successful Therapy ◽

Adverse fetal and infant outcomes among HIV-infected women who received either nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based antiretroviral therapy for prevention of mother-to-child transmission

AIDS ◽

10.1097/qad.0000000000001816 ◽

2018 ◽

Vol 32 (12) ◽

pp. 1625-1632

Author(s):

Rose Masaba ◽

Craig B. Borkowf ◽

Sonali Girde ◽

Clement Zeh ◽

Richard Ndivo ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Mother To Child Transmission ◽

Child Transmission ◽

Infant Outcomes ◽

Reverse Transcriptase Inhibitor ◽

Mother To Child

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227*

HIV Medicine ◽

10.1111/j.1468-1293.2008.00644.x ◽

2008 ◽

Cited By ~ 4

Author(s):

K Ruxrungtham ◽

RJ Pedro ◽

GH Latiff ◽

F Conradie ◽

P Domingo ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Reverse Transcriptase Inhibitors ◽

Nucleoside Reverse Transcriptase Inhibitors ◽

Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)

Current Opinion in HIV and AIDS ◽

10.1097/coh.0b013e328331b911 ◽

2009 ◽

Vol 4 (6) ◽

pp. 507-512 ◽

Cited By ~ 8

Author(s):

Jose R Arribas

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Drug Resistant ◽

Resistant Virus ◽

Drug Classes ◽

Traditional Drug ◽

Reverse Transcriptase Inhibitor ◽

Drug Resistant Virus

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

The Lancet ◽

10.1016/s0140-6736(06)69074-0 ◽

2006 ◽

Vol 368 (9532) ◽

pp. 287-298 ◽

Cited By ~ 60

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Randomised Trial ◽

Transcriptase Inhibitor ◽

Open Label ◽

Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060

PLoS ONE ◽

10.1371/journal.pone.0165140 ◽

2016 ◽

Vol 11 (12) ◽

pp. e0165140 ◽

Cited By ~ 8

Author(s):

Charlotte V. Hobbs ◽

Erin E. Gabriel ◽

Portia Kamthunzi ◽

Gerald Tegha ◽

Jean Tauzie ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Hiv Protease ◽

Hiv Protease Inhibitor ◽

Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients

HIV Medicine ◽

10.1111/j.1468-1293.2005.00315.x ◽

2005 ◽

Vol 6 (6) ◽

pp. 388-395 ◽

Cited By ~ 3

Author(s):

L Cuzin ◽

P Pugliese ◽

F Bugnon ◽

C Delpierre ◽

E Cua ◽

...

Keyword(s):

Reverse Transcriptase ◽

Prospective Cohort ◽

Transcriptase Inhibitor ◽

First Line ◽

Therapy Efficacy ◽

First Line Therapy ◽

Line Therapy ◽